Sei Network, a Layer-1 blockchain optimized for fast trade execution, has reached $15.9 billion in cumulative decentralized exchange (DEX) volume as of October 19, 2026. Nearly all recent trading activity occurs on Saphyre, the network's leading DEX, which accounted for $276 million of the $278 million monthly volume. Despite high trading volume, the total value locked (TVL) in Sei's DeFi protocols remains modest at $31.71 million, raising questions about future growth in assets versus trading activity. The network's rapid volume growth—from $4 billion in early 2025 to nearly $16 billion now—reflects strong trader interest, but the concentration of volume on one exchange poses operational risks.
Sei Network's decentralized exchange volume has neared $16 billion in cumulative DEX volume as of October 19, 2026. For readers following the broader cryptocurrency market, here is Pluang's market snapshot as of Oct 20, 2026 04:42 WIB: out of 50 major cryptocurrencies, 46 rose and 3 fell today. Notable movers include BAT with a 15.27% gain at Rp3.544, CRV up 11.35% at Rp6.603, and BAL rising 11.14% at Rp16.297.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
